Annexon, Inc. (ANNX): EBITDA
-$214.24M
Year ended 2025-12-31
-$208.39M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$214.24M | n/m | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | -$151.92M | n/m | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | -$141.57M | n/m | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | -$143.49M | n/m | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | -$128.57M | n/m | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | -$62.80M | n/m | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | -$32.02M | n/a | 2021-03-25, From 2019-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Annexon, Inc. (ANNX) | 2025-12-31 | -$214.24M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$123.80M | n/m |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | -$67.74M | n/m |
| Nektar Therapeutics (NKTR) | 2025-12-31 | -$139.08M | n/m |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$80.76M | n/m |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | -$132.22M | n/m |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | -$73.23M | n/m |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | -$58.89M | n/m |
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | -$110.31M | n/m |
Compare ANNX, TNXP, CTNM, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗